Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RAMUCIRUMAB for Squamous cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 9 adverse event reports in the FDA FAERS database where RAMUCIRUMAB was used for Squamous cell carcinoma.

Most Reported Side Effects for RAMUCIRUMAB

Side Effect Reports % Deaths Hosp.
Malignant neoplasm progression 743 13.9% 343 243
Death 492 9.2% 492 51
Interstitial lung disease 269 5.0% 55 131
Febrile neutropenia 229 4.3% 70 148
Neutropenia 229 4.3% 45 58
Decreased appetite 187 3.5% 37 96
Diarrhoea 186 3.5% 34 92
Hypertension 175 3.3% 31 58
Pyrexia 161 3.0% 27 107
Nausea 160 3.0% 39 69
Fatigue 159 3.0% 28 55
Disease progression 153 2.9% 39 31
Ascites 152 2.8% 40 74
Neutrophil count decreased 150 2.8% 30 72
Off label use 148 2.8% 30 49

Other Indications for RAMUCIRUMAB

Gastric cancer (1,257) Product used for unknown indication (780) Non-small cell lung cancer (405) Lung neoplasm malignant (304) Adenocarcinoma gastric (264) Colon cancer (222) Gastric cancer stage iv (178) Oesophageal adenocarcinoma (158) Hepatocellular carcinoma (156) Metastatic gastric cancer (156)

Other Drugs Used for Squamous cell carcinoma

CARBOPLATIN (608) CISPLATIN (522) PACLITAXEL (496) PEMBROLIZUMAB (470) FLUOROURACIL (430) NIVOLUMAB (343) CETUXIMAB (283) CEMIPLIMAB-RWLC (234) DOCETAXEL (198) GEMCITABINE (109)

Related Pages

RAMUCIRUMAB Full Profile All Squamous cell carcinoma Drugs RAMUCIRUMAB Demographics RAMUCIRUMAB Timeline